Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma

Author： Chetty Chandramu   Rao Jasti S   Lakka Sajani S  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.4, 2011-04, pp. : 535-546

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

By Danesi Romano   Altavilla Giuseppe   Giovannetti Elisa   Rosell Raffael  

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 69-80

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics of Non-Small Cell Lung Cancer

By  

Current Pharmacogenomics, Vol. 5, Iss. 3, 2007-09 ,pp. : 228-234

Bentham Science Publishers

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li   de Boer Richard H  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta   Santarpia Mariacarmela   Rosell Rafael  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite